Document:

rmti_Ex10_16

		
			Exhibit 10.16
		

		
			Employee Grantee:                    
		

		
			Grant Date:                 
		

		
			Number of Option Shares:                       
		

		
			Exercise Price Per Share:  $                    
		

		
			STOCK OPTION AGREEMENT
		

		
			THIS STOCK OPTION AGREEMENT, dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc., a Michigan corporation (the “Company”), and the individual set forth above, who is an employee of the Company (the “Optionee”). Any capitalized terms used herein but not otherwise defined shall have the meaning set forth in the Company’s 2018 Long Term Incentive Plan (the “Plan”).
		

		
			WHEREAS, the Plan was approved and adopted by the Company’s Board of Directors (the “Board”) and approved by the Company’s shareholders at the Company’s 2018 annual shareholders meeting (“Annual Meeting”);
		

		
			WHEREAS, the Company wishes to afford the Optionee the opportunity to purchase shares of its common stock (the “Common Stock”) pursuant to the terms and conditions of this Agreement and the Plan, the terms of which are hereby incorporated by reference and made a part of this Agreement; and
		

		
			WHEREAS, the Committee and the Board have determined that it would be in the best interest of the Company and its shareholders to grant this Option provided for herein to the Optionee as an incentive for increased efforts during his or her employment with the Company, have approved the grant of this Option on the Grant Date and have advised the Company thereof and instructed the undersigned officer to issue said Option.
		

		
			NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree as follows:
		

		
			ARTICLE I
		

		
			OPTION GRANT
		

		
			1.1.    Grant of Options.  For good and valuable consideration, on and as of the date hereof, the Company grants to the Optionee a Nonqualified Stock Option to purchase the number of shares of Common Stock set forth above upon the terms and conditions set forth in this Agreement (this “Option”).
		

		
			1.2    Exercise Price.  Subject to Section 2.1, the exercise price of the shares of Common Stock covered by this Option shall be the price per share set forth above without commission or other charge (which is the Fair Market Value per share of the Common Stock on the Grant Date).
		

		
			ARTICLE II
		

		
			ADJUSTMENTS
		

		
			2.1.    Adjustments to Option.  In the event of a merger, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash, shares or other property), stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting the Common Stock or the value thereof, such adjustments and other substitutions shall be made to this Option as the Committee, in its sole discretion, deems equitable or appropriate, including
		

		
			
		

		
			

		 

 

		

		
			adjustments in the number, class, kind and exercise price of securities subject to this Option (including, if the Committee deems appropriate, the substitution of similar options to purchase the shares of another company, as the Committee may determine to be appropriate in its sole discretion).
		

		
			ARTICLE III
		

		
			PERIOD OF EXERCISABILITY
		

		
			3.1.    Exercisability of Option.
		

		
			(a)  This Option shall vest and become exercisable in accordance with the following vesting schedule: (1) one-third (thirty-three and one-third percent) of the shares of Common Stock subject to this Option shall vest on the first anniversary of the Grant Date; (2) the next one-third (thirty-three and one-third percent) of the shares of Common Stock subject to this Option shall vest on the second anniversary of the Grant Date; and (3) the final one-third (thirty-three and one-third percent) of the shares of Common Stock subject to this Option shall vest on the third anniversary of the Grant Date (each anniversary, the “Vesting Date(s)”), so long as the Optionee continues to serve as an employee through such dates. If the Optionee’s service as am employee terminates prior to the applicable Vesting Date, then the unvested portion of this Option shall terminate and shall not be exercisable.  If the Optionee’s service as an employee terminates after an applicable Vesting Date for any reason, then the vested portion of this Option shall continue to be exercisable for a period of ninety (90) days following the employee’s termination. Notwithstanding the foregoing, if the Optionee’s service as an employee terminates after the Grant Date and prior to the Vesting Date, the Committee shall have the discretion to vest all or any portion of this Option and all or any such portion so vested of this Option shall continue to be exercisable until the expiration date of this Option.
		

		
			(b)  Notwithstanding (a), this Option shall become immediately vested and exercisable as to 100% of the shares of Common Stock subject to such Option if the Optionee ceases to be an employee due to Optionee’s death or Disability prior to the applicable Vesting Date.
		

		
			3.2    Change in Control.  Upon a Change in Control, this Option shall be treated in accordance with the terms of Section 10.2 of the Plan.
		

		
			3.3.    Expiration Date.  The Option may not be exercised after the first to occur of the following events and shall in no event be exercisable after the tenth anniversary of the Grant Date:
		

		
			(a)  If, prior to the date when the Option first becomes exercisable, Optionee’s employment terminates for any reason or if Optionee’s employment is terminated for Cause, Optionee’s right to exercise the Option shall terminate and all rights thereunder shall cease; or
		

		
			(b)  If, on or after the date when the Option first becomes exercisable, Optionee’s employment terminates for any reason, Optionee, or the person or persons to whom the Option shall have been transferred by will or the laws of descent and distribution, shall have the right, within three months after termination of employment to exercise the Option to the extent that it
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			was or became exercisable on the date of Optionee’s termination of employment, subject to any other limitation on the exercise of the Option in effect on the date of exercise.
		

		
			ARTICLE IV
		

		
			EXERCISE OF OPTION
		

		
			4.1.    Person Eligible to Exercise.  During the lifetime of the Optionee, only the Optionee may exercise this Option or any portion thereof. After the death of the Optionee, any exercisable portion of this Option may, prior to the time when this Option becomes unexercisable under Section 3.3, be exercised by his or her personal representative or by any person empowered to do so under the Optionee’s will or under the then applicable laws of descent and distribution.
		

		
			4.2.    Partial Exercise.  Any exercisable portion of this Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time (subject to any Company trading window limitations) prior to the time when this Option becomes unexercisable under Section 3.3 of this Agreement; provided, however, that any partial exercise shall be for whole shares of Common Stock only.
		

		
			4.3.    Manner of Exercise.  The exercise price for shares of Common Stock to be acquired upon exercise of this Option shall be paid in full in any manner permitted by the Plan.
		

		
			4.4.    Conditions to Issuance of Stock.  The Company shall not be required to issue or deliver any stock purchased upon the exercise of this Option or portion thereof prior to fulfillment of all of the following conditions:
		

		
			(a)    The obtaining of approval or other clearance from any state or federal governmental agency or Stock Exchange which the Committee shall, in its reasonable and good faith discretion, determine to be necessary or advisable; and
		

		
			(b)    The receipt by the Company of such assurance of compliance with federal and state securities laws as it may deem necessary or advisable.
		

		
			4.5.    Rights as Shareholder.  Optionee shall not be, nor have any of the rights or privileges of, a shareholder of the Company in respect of any shares purchasable upon the exercise of this Option or any portion thereof unless and until a certificate or certificates representing such shares shall have been issued by the Company to the Optionee or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian.  The Company shall not be liable to the Optionee for damages relating to any delay in issuing shares or a stock certificate to Optionee, any loss of a certificate, or any mistakes or errors in the issuance of shares or a certificate to Optionee.
		

		
			4.6.    Withholding.  To the extent applicable, the Company shall have the right to withhold from Optionee’s compensation or to require Optionee to remit sufficient funds to satisfy applicable withholding tax obligations upon the exercise of this Option. Subject to the limitations in Section 11.5 of the Plan, Optionee may, in order to fulfill the withholding obligation, make payment to the Company in any manner permitted under Section 11.5 of the Plan.  The Company shall not withhold from the exercise of this Option more shares than are
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			necessary to meet the established tax withholding requirements of federal, state and local obligations and pay the exercise price of this Option.  The Company shall be authorized to take any such action as may be necessary, in the opinion of the Company’s counsel, to satisfy the Company’s obligations for payment of such taxes.
		

		
			ARTICLE V
		

		
			MISCELLANEOUS
		

		
			5.1.    Option Not Transferable.  Neither this Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Optionee or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect; provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution, or transfers to which the Committee has given prior written consent subject to the conditions set forth in Section 11.3(a) of the Plan.
		

		
			5.2.    Notices.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Optionee shall be addressed to him or her at the address stated in the Company’s employee records. By a notice given pursuant to this Section 5.2, either party may hereafter designate a different address for notices to be given to the party. Any notice, which is required to be given to the Optionee, shall, if the Optionee is then deceased, be given to the Optionee’s personal representative if such representative has previously informed the Company of his or her status and address by written notice under this Section 5.2. Any notice shall have been deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service or when delivered personally to the Secretary or Optionee.
		

		
			5.3.    Amendment.  This Agreement may be amended only as provided herein or in the Plan.
		

		
			5.4.    Governing Law.  The laws of the State of Michigan shall govern the interpretation, validity and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.
		

		
			5.5    No Guarantee of Employment.  Nothing in this Agreement or in the Plan shall confer upon the Optionee any right to continue in the employment of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which are hereby expressly reserved, to terminate the employment of the Optionee at any time for any reason whatsoever, with or without cause, subject to the applicable provisions of, if any, the Optionee’s employment agreement with the Company.
		

		
			5.6    Plan Terms Control.  In the event of any conflict between the Plan and this Agreement, the terms of the Plan shall control, it being understood that variations in this
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			Agreement from terms set forth in the Plan shall not be considered to be in conflict if the Plan permits such variations.
		

		
			5.7    Clawback Policy.  This Agreement, the Option and any economic benefits recognized by Optionee in connection with the Option are subject to the Company’s Clawback Policy as provided in the Company’s Principles of Corporate Governance from time to time.
		

		
			IN WITNESS WHEREOF, the parties have executed this Agreement as of the Grant Date.
		

		
			 
		

			
					
						 

					
					
						ROCKWELL MEDICAL, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Name: Stuart Paul

				
	
					
						 

					
					
						 

					
					
						Title:   President & CEO

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						OPTIONEE:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						[Name]

				

		
			 
		

		 

		

			5rmti_Ex10_34

		
			Exhibit 10.34
		

		
			CONFIDENTIAL
		

		
			MASTER SERVICES AND IP AGREEMENT
		

		
			This Master Services and IP Agreement (the “Agreement”) is effective October 7, 2018 (“Effective Date”) by and between Charak, LLC, whose legal address is 2505 Seascape Drive, Las Vegas, NV 89128, Dr. Ajay Gupta, an individual, having a principle residence at 2505 Seascape Drive, Las Vegas, Nevada 89128 (hereafter “Dr. Gupta”) (Dr. Gupta and Charak, LLC are collectively herein “Charak”), and Rockwell Medical, Inc., having a principal place of business at 30142 Wixom Road, Wixom, Michigan 48393 (“Rockwell”). Charak and Rockwell are each a “Party” and collectively the “Parties.” The Parties agree as follows:
		

		
			RECITALS
		

		
			WHEREAS, Charak, Dr. Gupta, and Rockwell entered in a License Agreement, dated January 7, 2002 (as amended, “2002 Agreement”) relating to Triferic® soluble ferric pyrophosphate, which was licensed from Charak to Rockwell;
		

		
			WHEREAS, Dr. Gupta joined Rockwell as the Chief Scientific Officer, effective June 16, 2009, in accordance with an agreement memorialized in an email exchange dated June 18, 2009 (“Letter Agreement”) and has served since that time as an officer and fiduciary of the Company;
		

		
			WHEREAS, Dr. Gupta executed an Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition Agreement  (“Invention Agreement”), which was dated as of June 16, 2009; and
		

		
			WHEREAS, the Parties now wish to clarify and further establish their respective rights and obligations with regard to the foregoing, as well as to license certain additional intellectual property rights to the Company, as described herein.
		

		
			AGREEMENT
		

		
			THEREFORE, for good and valuable consideration set forth herein, the receipt and sufficiency of which is acknowledged, the Parties hereby agree as follows:
		

		
			1.         Entry into 2018 Agreements.  Concurrent with and contingent upon the execution and delivery of this Agreement, the Parties will execute and deliver the following agreements, each in the form attached hereto (collectively with this Agreement, the “2018 Agreements”):
		

		
			(a)        That certain Employment Agreement, in the form attached hereto as Exhibit A, pursuant to which Dr. Gupta will serve as Rockwell’s Senior Vice President and Chief Scientific Officer; and
		

		
			(b)        That certain Commercialization and Technology License Agreement – IV-Triferic® in the form attached hereto as Exhibit B;
		

		
			(c)        That certain Technology License Agreement – TPN-Triferic® in the form attached hereto as Exhibit C; and
		

		
			
		

		
			

		 

		

			Page 1

		

 

		

		
			(d)        That certain Amendment to License Agreement – Dialysate Triferic® in the form attached hereto as Exhibit D.
		

		
			2.         Payments.
		

		
			(a)        In consideration of the covenants, conditions, terms and releases set forth in this Agreement, Rockwell will pay the following sums to Charak:
		

		
			(i)         One million dollars ($1,000,000), which is non-refundable and is not an advance against royalties, with such sum to be paid by Rockwell in four quarterly installments of $250,000 each, with the first installment due October 15, 2018 and the subsequent three installments due on January 15, 2019, April 15, 2019 and July 15, 2019; and
		

		
			(ii)       Up to $100,000 in reimbursement for legal fees incurred by Charak leading up to and in connection with the negotiation of the 2018 Agreements, with such amount to be paid within thirty (30) days following presentation of legal bills by Charak to Rockwell.
		

		
			3.         Reservation of Rights. Rockwell expressly acknowledges and agrees that Charak shall have all rights vis-à-vis Rockwell (to the extent actually or purportedly owned or controlled by Rockwell as of the Effective Date) to independently research, develop, make, have made, use, sell, offer to sell, and import products including Spironolactone+indapamide or Eplerenone+Indapamide (referring to the diuretic combination patent), which Dr. Gupta listed as an exception in the Invention Agreement.
		

		
			4.         Representations and Warranties.
		

		
			(a)        Dr. Gupta and Charak represent and warrant that they do not own or control, directly or indirectly, any patents, patent applications, know-how, trade secrets or other intellectual property rights, other than those licensed to Rockwell under the 2018 Agreements, that Rockwell may reasonably require or find useful in the manufacture, import, use and/or sale of any “Licensed Products” (as such term and its derivatives thereof is defined in the 2018 Agreements).
		

		
			(b)        Each Party represents and warrants that: (i) it has the necessary individual, corporate or limited liability company power and authority to enter into the 2018 Agreements; (ii) the 2018 Agreements are valid and binding obligations against such Party, enforceable in accordance with their applicable terms; and (iii) such Party possesses and controls all right, title and interest in the intellectual property and other assets and rights that are the subject of the 2018 Agreements such that the Party has the right to, and will, convey all such rights contemplated thereunder, free and clear of any encumbrances, liens or adverse claims that may be asserted by any third party.
		

		
			
		

		
			

		 

		

			Page 2

		

 

		

		
			5.         Release of Claims.
		

		
			(a)        In consideration for the payments set forth in Section 2, Charak and Dr. Gupta, each on their own behalf, and on behalf of their respective heirs, successors, subsidiaries, affiliates, assigns, agents, officers, directors, employees and related entities, hereby releases, remises, acquits, forever discharges and covenants not to sue Rockwell, and its current and former officers, directors, employees, attorneys, agents, representatives, affiliated entities, subsidiaries, successors and assigns from any and all claims, demands, causes of action, suits, debts, obligations, choses in action, liabilities, damages, interest, fees, costs, expenses and rights whatsoever, in law or equity, known or unknown, suspected or unsuspected, previously existing or existing as of the Effective Date of this Agreement arising out of or relating to any acts, errors, omissions, contracts (including the 2002 Agreement, Letter Agreement, and Invention Agreement), torts, federal or state statute, to the extent that such claims arose or could have been asserted prior to the Effective Date.
		

		
			(b)        In consideration for the execution and delivery of the 2018 Agreements, Rockwell on its own behalf, and on behalf of its respective successors, subsidiaries, affiliates, assigns, agents, officers, directors, employees and related entities, hereby releases, remises, acquits, forever discharges and covenants not to sue Charak, Dr. Gupta or their respective heirs, successors, subsidiaries, affiliates, assigns, agents, officers, directors, employees and related entities, from any and all claims, demands, causes of action, suits, debts, obligations, choses in action, liabilities, damages, interest, fees, costs, expenses and rights whatsoever, past, present or future, contingent or non-contingent, in law or equity, known or unknown, suspected or unsuspected, previously existing or existing as of the Effective Date of this Agreement arising out of or relating to (i) Dr. Gupta’s actual or alleged unwillingness to assign certain inventions to Rockwell to the extent that such inventions are now being licensed to Rockwell under the 2018 Agreements or included within the permitted carve-out under Section 3 of this Agreement, and (ii) Dr. Gupta’s actual or alleged failures to fulfill duties or obligations to Rockwell in association with the 2002 Agreement, Letter Agreement, and/or Invention Agreement.
		

		
			6.         Notice and Cure of Breach; Termination Rights.
		

		
			(a)        Notwithstanding anything to the contrary in the 2018 Agreements or the 2002 Agreement, if any Party thereto is in material breach of its obligations thereunder, then the non-breaching Party may deliver notice of such breach to the other Party (“Notice of Dispute”). The allegedly breaching Party shall have up to 120 days (or 45 days in the case of any payment breach) to cure such breach from the receipt of the Notice of Dispute; provided, that if such breach is capable of being cured but cannot reasonably be cured within such 120-day period, the breaching Party may cure such breach during an additional period as is reasonable in the circumstances by initiating actions to cure such breach during such 120-day period and using reasonable efforts to pursue such actions. Subject to Section 6(b), if the allegedly breaching Party fails to cure that breach within the applicable period set forth above, then the Party originally delivering the Notice of Dispute may terminate the applicable agreement on written notice of termination.
		

		
			(b)        Any right to terminate one of the 2018 Agreements or the 2002 Agreement shall be stayed and the applicable cure period tolled for the applicable negotiation and mediation
		

		
			
		

		
			

		 

		

			Page 3

		

 

		

		
			periods only if, during such cure period, the Party alleged to have been in material breach shall have initiated dispute resolution procedures, in accordance with the applicable agreement (Section 6(c) for this Agreement) with respect to the alleged breach, which stay and tolling shall continue until such dispute has been fully resolved.  If a Party is then determined to be in material breach of such agreement, the non-breaching Party may terminate such agreement if the breaching Party fails to cure the breach within 30 days after the conclusion of the dispute resolution negotiation and mediation procedures (and such termination shall then be effective upon written notification from the notifying Party to the breaching Party).
		

		
			(c)        In the event of a disagreement between the Parties that cannot be otherwise resolved either party may, or in the event of the allegedly breaching Party fails to cure that breach within the applicable period set forth in Section 6(b), the Parties shall have such dispute referred to their respective senior officials designated below for attempted resolution by good faith in-person negotiations within sixty (60) days (“Negotiation Period”).  Said designated senior officials are as follows: For Rockwell: Chief Executive Officer; For Dr. Gupta: himself; For Charak: Dr. Gupta; (or a designated senior executive with decision-making authority). In the event the designated senior officials are not able to resolve a Dispute identified in a Notice of Dispute under Section 6(a), and after an in-person meeting within the sixty (60) day period, either Party may invoke the provisions of this Section 6(d).
		

		
			(d)        If a settlement under Section 6(c) is not achieved by the conclusion of the Negotiation Period, either Party may demand the Dispute be submitted for resolution to mediation to occur at a mutually agreed upon location before a mutually agreed mediator within 60 days. Each Party shall bear its own expenses for mediation other than the Parties will share the cost of the mediator. The Parties reserve all rights to adjudicate any dispute not resolved by mediation.
		

		
			7.         No Slander or Defamation.  To the fullest extent permitted by law, and except as to statements made in legal, administrative or arbitral proceedings in disputes between the Parties and truthful testimony, each Party agrees that it will not defame, disparage or otherwise speak of the other Party(ies) and/or their products or services in a false or misleading manner, including but not limited to through any media, social media, Facebook, Twitter or similar mechanism.
		

		
			8.         Miscellaneous
		

		
			(a)        The 2018 Agreements and the 2002 Agreement (as amended hereby and thereby) contains the entire understanding of the Parties and supersedes all prior agreements, arrangements and understandings between the Parties with regard to the subject matter of the 2018 Agreements and the 2002 Agreement; there are no representations, warranties, covenants, or undertakings other than those expressly set forth herein or therein.
		

		
			(b)        The Parties acknowledge that in executing this Agreement, they have carefully reviewed and had the opportunity to review the terms of this Agreement, with counsel of their choice and are fully aware of the extent of their rights and obligations under this Agreement. The Parties further agree that the language of this Agreement shall not be construed presumptively against any of the Parties to this Agreement. This Agreement shall not constitute an admission by one Party of any allegation against any other Party, shall not be considered as an admission of
		

		
			
		

		
			

		 

		

			Page 4

		

 

		

		
			liability other than terms specifically agreed in this Agreement, nor shall it be considered an admission of wrongdoing or anything improper.
		

		
			(c)        The Parties agree that this Agreement may be executed in two or more counterparts, each of which shall constitute and original and binding copy of this Agreement, albeit one and the same instrument. Executed photocopies of this Agreement shall be as binding as the original.
		

		
			(d)        This Agreement will be construed, interpreted, and applied in accordance with the laws of the State of Delaware, excluding any choice of law rules that would direct the application of the laws of another jurisdiction. Any litigation arising under or relating to this Agreement shall be filed in federal or state court in Wilmington, Delaware, which the Parties agree shall be the exclusive venue for claims arising hereunder. In resolving any dispute arising under or relating to this Agreement, the court shall be entitled to award the prevailing Party its reasonable fees and expenses, including attorneys’ fees.
		

		
			(e)        No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by all Parties hereto.
		

		
			(f)        If one or more provisions of this Agreement are held to be invalid or unenforceable under applicable law, such provisions shall be construed, if possible, so as to be enforceable under applicable law, or such provisions shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.
		

		
			(g)        This Agreement shall be binding upon and inure to the benefit of the beneficiaries, heirs and representatives of Charak (including the Dr. Gupta) and the successors and assigns of Charak. This Agreement shall be binding and enforceable upon any successor of Rockwell in accordance with the operation of law.
		

		
			(h)        All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered by email, hand or mailed within the continental United States by first class certified mail, return receipt requested, postage prepaid, addressed as follows:
		

		
			if to Rockwell:
		

		
			Rockwell Medical, Inc.
		

		
			30142 Wixom Road
		

		
			Wixom, Michigan 48393
		

		
			Attn:  President
		

		
			 
		

		
			
		

		
			

		 

		

			Page 5

		

 

		

		
			if to Charak or Dr. Gupta:
		

		
			Dr. Ajay Gupta
		

		
			2505 Seascape Drive
		

		
			Las Vegas, Nevada  89128
		

		
			 
		

		
			With a Copy to:
		

		
			Holley Driggs Walch
		

		
			400 South Fourth Street, Suite 300
		

		
			Las Vegas, Nevada 89101
		

		
			Attn:  James D. Boyle, Esq.
		

		
			 
		

		
			In Witness Whereof, and intending to be legally bound, each of the Parties hereto has caused this Agreement to be executed as of the date(s) set forth below.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						CHARAK, LLC

					
					
						ROCKWELL MEDICAL, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By

					
					
						            /s/ Ajay Gupta

					
					
						By

					
					
						           /s/ Benjamin Wolin

				
	
					
						 

					
					
						Name: Ajay Gupta

					
					
						 

					
					
						Name: Benjamin Wolin

				
	
					
						 

					
					
						Title:    Manager

					
					
						 

					
					
						Title:    Chairman

				
	
					
						 

					
					
						Date:    October 7, 2018

					
					
						 

					
					
						Date    October 7, 2018

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						DR. AJAY GUPTA

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						          /s/ Ajay Gupta

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Date: October 7, 2018

					
					
						 

					
					
						 

				

		
			 
		

		 

		

			Page 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]